Apnimed Closes Upsized IPO at $16, Raises $220.8M with Full Overallotment
APMD is trading near its 52-week low of $22.35 (12% above the low).
Summary
Apnimed closed its upsized IPO, selling 13.8M shares at $16 — the top of the range — for $220.8M in gross proceeds. The deal included full exercise of the underwriters' 1.8M-share overallotment option, adding $28.8M beyond the base offering. This follows the July 31 pricing and confirms strong demand for the late-stage sleep apnea biotech. With AD109's PDUFA date set for February 28, 2027, the capital strengthens the balance sheet ahead of a potential commercial launch.
At the time of this announcement, APMD was trading at $25.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $950M. The 52-week trading range was $22.35 to $27.91. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.